Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway

Targeting FGFR inhibition in cholangiocarcinoma

(2021) Lipika Goyal et al.   CANCER TREATMENT REVIEWS

HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc

(2021) Zhipeng Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways

(2021) Tianli Chen et al.   MOLECULAR THERAPY

FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis

(2021) Tianli Chen et al.   ONCOGENE

Pemigatinib: First Approval

(2020) Sheridan M. Hoy   DRUGS

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

(2020) Phillip C. C. Liu et al.   PLoS One

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

(2020) Ian M. Silverman et al.   Cancer Discovery

Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1

(2019) Zengli Liu et al.   EBioMedicine

Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway

(2019) Rongqi Sun et al.   EBioMedicine

Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle

(2019) Bo Qiu et al.   EBioMedicine

HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium

(2018) Yun-Fei Xu et al.   ONCOGENE

SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance

(2018) Xiaodong Yuan et al.   BRITISH JOURNAL OF CANCER

FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1

(2017) Tingting Huang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β

(2017) Wen Min Lau et al.   MOLECULAR CANCER THERAPEUTICS

Cholangiocarcinoma — evolving concepts and therapeutic strategies

(2017) Sumera Rizvi et al.   Nature Reviews Clinical Oncology

Mechanism of FGF receptor dimerization and activation

(2016) Sarvenaz Sarabipour et al.   Nature Communications

Transcription factors SOX4 and SOX9 cooperatively control development of bile ducts

(2015) Alexis Poncy et al.   DEVELOPMENTAL BIOLOGY

FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder

(2015) Eric W. Fan et al.   JOURNAL OF UROLOGY

Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma

(2014) Yun-Fei Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Sox9 and programming of liver and pancreatic progenitors

(2013) Yoshiya Kawaguchi   JOURNAL OF CLINICAL INVESTIGATION

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

Intrahepatic Bile Ducts Develop According to a New Mode of Tubulogenesis Regulated by the Transcription Factor SOX9

(2009) Aline Antoniou et al.   GASTROENTEROLOGY

Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating  -Catenin Signaling

(2008) R. Pai et al.   CANCER RESEARCH